GSK Investigational Site

Verona, Veneto 37135

0 studies enrolling now · 10 studies all time

What they study most

Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anaemia, Arthritis, Rheumatoid, HIV Infection, Infection, Human Immunodeficiency Virus I, Infections, Intestinal, Multiple Sclerosis

Studies at this site

• Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors — Completed
• Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD) — Completed
• New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects — Completed
• Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis — Completed
• Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis — Completed
• A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease — Completed
• GSK2251052 in the Treatment of Complicated Intra-abdominal Infections — Stopped early
• Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease — Completed
• First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis — Completed
• Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients — Completed